BRIEF published on 09/24/2024 at 23:05, 2 years 1 month ago Theralase clôture un placement privé sans intermédiaire et émet des options sur actions Placement Privé Sans Intermédiaire Technologies Théralase Options Sur Actions Financement De La Recherche Clinique Étude Sur Le Cancer De La Vessie
BRIEF published on 09/24/2024 at 23:05, 2 years 1 month ago Theralase Closes Non-Brokered Private Placement and Issues Stock Options Stock Options Non-brokered Private Placement Theralase Technologies Clinical Research Funding Bladder Cancer Study
PRESS RELEASE published on 09/24/2024 at 23:00, 2 years 1 month ago Theralase(R) Closes Non-Brokered Private Placement and Issues Stock Options Theralase Technologies Inc. successfully closes Non-Brokered Private Placement offering of units for cancer research and development Private Placement Pharmaceutical Company Theralase Technologies Inc. Clinical Study Cancer Research
BRIEF published on 09/19/2024 at 23:10, 2 years 2 months ago Theralase® prolonge ses mandats Extension Bourse De Croissance TSX Technologies Théralase Bons De Souscription D'actions Développement Pharmaceutique
BRIEF published on 09/19/2024 at 23:10, 2 years 2 months ago Theralase® Extends Warrants Share Purchase Warrants TSXV Extension Theralase Technologies Pharmaceutical Development
PRESS RELEASE published on 09/19/2024 at 23:05, 2 years 2 months ago Theralase(R) Extends Warrants Theralase Technologies Inc. plans to extend expiry date of 10,000,000 share purchase warrants from Sept 22, 2024, to Sept 22, 2027. Warrants issued in 2022 at $0.35/share. TSXV approval pending TSX Venture Exchange Expiry Date Extension Theralase Technologies Inc. Share Purchase Warrants Clinical Stage Pharmaceutical Company
BRIEF published on 09/03/2024 at 13:05, 2 years 2 months ago Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus Theralase Ruvidar Antiviral Drug HSV-1 Acyclovir
BRIEF published on 09/03/2024 at 13:05, 2 years 2 months ago Ruvidar(TM) s'avère plus efficace que l'acyclovir dans la destruction du virus de l'herpès simplex Theralase Ruvidar Médicament Antiviral HSV-1 Acyclovir
PRESS RELEASE published on 09/03/2024 at 13:00, 2 years 2 months ago Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus Theralase Technologies Inc. announces preclinical superiority of Ruvidar TM in destroying HSV-1 virus, seeking partnerships for commercial development Theralase Technologies Inc. Preclinical Study Partnerships Ruvidar TM HSV-1 Virus
BRIEF published on 08/28/2024 at 13:05, 2 years 2 months ago Rutherrin® augmente l'efficacité de la chimiothérapie contre le cancer du poumon Theralase® Technologies Inc. Chimiothérapie CPNPC Rutherrine® Cisplatine
Published on 11/20/2026 at 15:00, 17 hours 34 minutes ago Jaguar Health, Inc. Announces Reverse Stock Split
Published on 11/20/2026 at 14:50, 17 hours 44 minutes ago Proposed Issue Of Payment-In-Kind Interest Shares Under Convertible Debenture
Published on 11/20/2026 at 14:00, 18 hours 34 minutes ago Dateline appoints Tony Ferguson as Acting Chairman
Published on 11/20/2026 at 13:30, 19 hours 4 minutes ago Collective Metals Enters Into Option to Acquire the Lac Tio West Property in Quebec
Published on 11/20/2026 at 13:30, 19 hours 4 minutes ago Alset AI Closes Non-Brokered Private Placement Offering
Published on 11/20/2026 at 23:45, 8 hours 49 minutes ago APEC CEO Summit 2026 Concludes Successfully in Shenzhen
Published on 11/20/2026 at 22:39, 9 hours 54 minutes ago ABIVAX: Abivax publie une déclaration concernant le rapport d'un vendeur à découvert
Published on 11/20/2026 at 21:36, 10 hours 58 minutes ago EQS-Adhoc: Global Health Care AG: Board of Directors proposes sale of milon stake based on an equity value of EUR 23.3 million – subscription right for all shareholders
Published on 11/20/2026 at 20:49, 11 hours 45 minutes ago E-PANGO: Jugement du Tribunal Judiciaire de Paris relatif au contentieux avec le groupement RIVP-HENEO-HSF
Published on 11/20/2026 at 18:34, 13 hours 59 minutes ago Déclaration hebdomadaire d'opérations effectuées du 16 au 20 novembre 2026
Published on 11/20/2026 at 18:34, 13 hours 59 minutes ago Disclosure of transactions in own shares from November 16 to November 20, 2026
Published on 11/20/2026 at 17:35, 14 hours 59 minutes ago Guillemot Corporation S.A. | Déclaration hebdomadaire des transactions sur actions propres du 16 au 20 novembre 2026
Published on 11/20/2026 at 17:35, 14 hours 59 minutes ago Guillemot Corporation S.A. | Weekly report share buyback from November 16 to November 20, 2026
Published on 11/19/2026 at 19:00, 1 day 13 hours ago MR.BRICOLAGE: OUTLOOK FOR THE 2026 FINANCIAL YEAR